Bicycle Therapeutics plc is a clinical-stage pharmaceutical company developing Bicycle molecules, a novel class of fully synthetic short peptides constrained to form two loops for high-affinity target binding. The company focuses on oncology indications with high unmet medical need, utilizing a proprietary phage display screening platform to identify candidates. Its pipeline includes Bicycle Drug Conjugates (BDC), such as nuzefatide pevedotin targeting EphA2 and zelenectide pevedotin targeting Nectin-4, and Bicycle Radioconjugates (BRC), including BT1702 targeting MT1-MMP. Bicycle also develops Bicycle Imaging Agents (BIA) and Bicycle Tumor-Targeted Immune Cell Agonists (TICA), such as BT7480. Founded in 2009 based on research by Sir Greg Winter and Professor Christian Heinis, the company collaborates with biopharmaceutical partners to explore applications in anti-infective, cardiovascular, ophthalmology, dementia, central nervous system, neuromuscular, and respiratory disease areas.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage bicycletherapeutics.com
Sector Healthcare IR page investors.bicycletherapeutics.com
Tags
oncology, bicyclic peptides, drug conjugates, radioconjugates, phage display, solid tumors, pancreatic cancer, urothelial cancer, breast cancer, non-small cell lung cancer, theranostics, immune cell agonists, Bicycle molecules, nuzefatide pevedotin, BT5528, BDC, BT1702, BRC, BIA, zelenectide pevedotin, BT7480, Bicycle TICA, Duravelo-2
Press page —

Metrics

Valuation  
Market cap $ 252.208M
Market cap (USD) $ 252.208M
P/E -1.78
PEG —
P/BV 0.50
P/S 3.02
P/OCF -1.44
P/FCF -1.42
Dividend yield —
Turnover / mcap —
Returns  
ROE -31.2%
ROI —
ROIC —
Profit margin -301.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -13.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 72.586M 35.275M 26.976M 14.463M 11.697M 10.39M 13.801M 7.136M
Net profit -218.96M -169.031M -180.664M -112.717M -66.819M -51.01M -30.608M -21.846M
Free cash flow -252.025M -165.959M -63.557M -105.098M -16.824M -18.989M -30.168M -27.264M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 7.08 14 18.08 29.6 60.87 17.95 9.43 —
Price performance 12m -0.49 -0.23 -0.39 -0.51 2.39 0.9 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 5.02M 201,000 5.46M 1M 2.05M 0.00 0.00 0.00
↳ YoY growth -96.0% +2,614.4% -81.7% +104.5% -100.0%
Borrowings, non-current (USD) — — — — 14.5M 29.9M 30.3M 30.7M — —
Lease liabilities (USD) — — — 1.89M 1.27M 14.5M 14M 14.3M 10.3M 17.5M
Cash and deposits (USD) 9.4M 67.7M 63.4M 0.00 0.00 439M 339M 526M 880M 628M
Right-of-use assets (USD) — — — 2.06M 1.29M 14.7M 13.7M 13.2M 7.67M 15.9M
Net debt (borrowings + leases - cash) (USD) — — — — 15.8M -394M -295M -481M — —
Cash flow detail
Operating cash flow (USD) — -1.42M -26.1M -28.6M -17.8M -14.8M -86.1M -60.6M -165M -250M
Purchases of property, plant and equipment (USD) — -1.11M -1.19M -1.56M -1.2M -2.03M -19M -2.93M -1.24M -2.35M
Change in receivables (cash effect) (USD) — — -400,000 4.91M -2.15M 4.54M -1.64M 2.48M — —
Change in payables (cash effect) (USD) — 67,000 -169,000 220,000 -663,000 1.2M 2.56M 8M 3.1M -6.87M
Interest paid (cash effect) (USD) — — — — -378,000 -2.52M -2.79M -2.75M -1.37M —
Income taxes paid (cash effect) (USD) — — -73,000 -117,000 -124,000 -73,000 -2.23M -562,000 -792,000 717,000
Share-based compensation (USD) — 515,000 1.02M 3.08M 6.51M 12.1M 26.8M 32.5M 38.1M 39.5M
Operating cash flow before change in receivables (USD) — — -25.7M -33.5M -15.6M -19.3M -84.5M -63.1M — —
Free cash flow (OCF - PPE - intangibles) (USD) — -2.53M -27.3M -30.2M -19M -16.8M -105M -63.6M -166M -252M
Income detail
Research and development expense (USD) — 11.9M 20.8M 25.5M 33.1M 44.9M 81.6M 156M 173M 240M
↳ 5y CAGR +47.1% +49.8% +46.6% +48.6%
Total comprehensive income (USD) — -13.9M -23.7M -30.4M -52.7M -67M -109M -182M -168M -223M
Comprehensive income to owners (USD) — -13.9M -23.7M -30.4M -52.7M -67M -109M -182M -168M -223M
Reported Mar 10, 2020 Mar 10, 2020 Mar 10, 2020 Mar 10, 2020 Mar 11, 2021 Mar 1, 2022 Feb 28, 2023 Feb 20, 2024 Feb 25, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

10/29/26

Download PDF

Nuzefatide pevedotin granted FDA Orphan Drug Designation for the treatment of pancreatic cancer; further updates expected in 2027

Initiation of the first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP targeting Bicycle® Radioconjugate, expected in 2H 2027

Cash and cash equivalents of $469.9 million as of September 30, 2026, with expected cash runway into 2030

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Oct. 29, 2026-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate updates.

“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands. We believe the FDA’s Orphan Drug Designation for nuzefatide in pancreatic cancer further supports our development strategy and underscores the significant unmet need in this patient population,” said Bicycle CEO Kevin Lee, Ph.D. “We remain focused on disciplined execution across our prioritized programs and believe our growing clinical data continue to demonstrate the potential of Bicycle® molecules to deliver highly targeted therapies with differentiated benefit/risk profiles. We look forward to advancing our pipeline and reaching important clinical milestones for nuzefatide and initiating our first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027.”

Third Quarter 2026 and Recent Events

  • **Nuzefatide pevedotin (nuzefatide), a potentially first-in-class EphA2 targeting Bicycle® Drug Conjugate (BDC®), was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.**In September 2026,the FDA granted nuzefatide ODD for the treatment of pancreatic cancer.The designation is granted to investigational therapies intended to treat rare diseases affecting fewer than 200,000 patients in the United States. The designation provides development incentives, including eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of market exclusivity upon regulatory approval.

Bicycle Therapeutics is actively enrolling patients in a Phase 2 clinical trial to evaluate efficacy, safety, and pharmacokinetics of nuzefatide in adult patients with recurrent pancreatic ductal adenocarcinoma (PDAC) and expects to provide further updates in 2027.

  • Bicycle Therapeutics continues to optimize its Bicycle® Radioconjugate (BRC®) molecules and advance its emerging radioligand pipeline, with initiation of the first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP-targeting BRC®, expected in the second half of 2027.

  • **Zelenectide pevedotin is a BDC® molecule targeting Nectin-4, a well-validated tumor antigen.**Bicycle Therapeutics converted the Duravelo-2 trial to a randomized Phase 2 trial in May 2026 and deprioritized the program for internal development. The company expects to report Duravelo-2 survival data from the randomized Phase 2 trial in previously untreated patients with metastatic urothelial cancer (mUC) in the second half of 2027.

Third Quarter 2026 Financial Results

  • Cash and cash equivalents were $469.9 million as of September 30, 2026, compared to $628.1 million as of December 31, 2025. The decrease in cash and cash equivalents is primarily due to cash used in operations, including cash payments for clinical program activities.

  • Collaboration revenue was $34.1 million for the three months ended September 30, 2026, compared to $11.7 million for the three months ended September 30, 2025. The increase in collaboration revenue was primarily due to the recognition of all remaining revenue under Bicycle Therapeutics’ collaboration with Bayer Consumer Care AG upon termination of the underlying collaboration agreement.

  • Research and development (R&D) expenses were $33.4 million for the three months ended September 30, 2026, compared to $58.4 million for the three months ended September 30, 2025. The decrease in expense of $25.0 million was primarily due to decreased clinical program expenses for zelenectide, decreased personnel-related costs and share-based compensation due to our workforce reductions announced in August 2025 and March 2026, as well as decreased discovery, platform and other expenses, offset by lower research and development incentives associated with the corresponding decrease in qualifying research and development expenses period over period.

  • General and administrative (G&A) expenses were $14.1 million for the three months ended September 30, 2026, compared to $18.9 million for the three months ended September 30, 2025. The decrease in expense of $4.8 million was primarily due to decreased personnel-related costs and share-based compensation due to our workforce reductions announced in August 2025 and March 2026.

  • Net loss was $10.5 million, or $(0.15) basic and diluted net loss per share, for the three months ended September 30, 2026, compared to net loss of $59.1 million, or $(0.85) basic and diluted net loss per share, for the three months ended September 30, 2025.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “promising,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of nuzefatide pevedotin, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and the potential development of nuzefatide pevedotin in pancreatic cancer; the clinical and regulatory benefits anticipated from the Orphan Drug Designation granted to nuzefatide pevedotin, including the potential for seven years of market exclusivity upon regulatory approval, eligibility for tax credits and exemption from certain FDA user fees; the progress of Bicycle Therapeutics’ clinical trials, reporting data from Bicycle Therapeutics’ clinical trials, including for nuzefatide pevedotin, and updates on future clinical development plans for nuzefatide pevedotin; the potential of Bicycle molecules to deliver highly targeted therapies with differentiated benefit/risk profiles; the positive properties of Bicycle® radioligand molecules for radiopharmaceutical use; the development of the Bicycle® radioligands pipeline, including BRCs, and the expected initiation of the first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027; communications with and feedback from the FDA and other regulatory agencies; Bicycle Therapeutics’ expected financial runway; and the use of Bicycle Therapeutics’ technology through various partnerships to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties related to the benefits and potential unintended consequences of the strategic reprioritization and recent workforce reductions; uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics may not realize the intended benefits of its technology or partnerships; the risk that Bicycle Therapeutics may not achieve any of its clinical development strategies; timing of results from clinical trials; whether the outcomes of preclinical studies and prior clinical trials will be predictive of future clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics’ projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle Therapeutics’ actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle Therapeutics’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on July 30, 2026, as well as in other filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

| Bicycle Therapeutics plcCondensed Consolidated Statements of Operations(In thousands, except share and per share data)****(Unaudited) |

| | | | | | | | | | | | | |

| | | | | | | | | | | | | |

| | | Three Months Ended | | Nine Months Ended |

| | | September 30, | | September 30, |

| | | 2026 | | 2025 | | 2026 | | 2025 |

| Collaboration revenue | | $ | 34,057 | | | $ | 11,734 | | | $ | 35,573 | | | $ | 24,631 | |

| Operating expenses: | | | | | | | | | | | | |

| Research and development | | | 33,422 | | | | 58,426 | | | | 123,483 | | | | 188,513 | |

| General and administrative | | | 14,112 | | | | 18,859 | | | | 45,608 | | | | 58,475 | |

| Total operating expenses | | | 47,534 | | | | 77,285 | | | | 169,091 | | | | 246,988 | |

| Loss from operations | | | (13,477 | ) | | | (65,551 | ) | | | (133,518 | ) | | | (222,357 | ) |

| Other income (expense): | | | | | | | | | | | | |

| Interest and other income | | | 4,213 | | | | 6,700 | | | | 13,450 | | | | 22,587 | |

| Interest expense | | | (45 | ) | | | (44 | ) | | | (137 | ) | | | (149 | ) |

| Total other income, net | | | 4,168 | | | | 6,656 | | | | 13,313 | | | | 22,438 | |

| Net loss before income tax provision | | | (9,309 | ) | | | (58,895 | ) | | | (120,205 | ) | | | (199,919 | ) |

| Provision for (benefit from) income taxes | | | 1,169 | | | | 205 | | | | 1,431 | | | | (1,113 | ) |

| Net loss | | $ | (10,478 | ) | | $ | (59,100 | ) | | $ | (121,636 | ) | | $ | (198,806 | ) |

| Net loss per share, basic and diluted | | $ | (0.15 | ) | | $ | (0.85 | ) | | $ | (1.74 | ) | | $ | (2.87 | ) |

| Weighted average ordinary shares outstanding, basic and diluted | | | 69,979,934 | | | | 69,303,746 | | | | 69,823,830 | | | | 69,251,291 | |

| | | | | | | | | | | | | |

| Balance Sheets Data**(In thousands)****(Unaudited)** |

| | | | | | | |

| | | | | | | |

| | | September 30, | | December 31, |

| | | 2026 | | 2025 |

| Cash and cash equivalents | | $ | 469,928 | | $ | 628,110 |

| Working capital | | | 493,097 | | | 625,901 |

| Total assets | | | 567,179 | | | 717,597 |

| Total shareholders’ equity | | | 505,277 | | | 609,977 |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029336969/en/

Investors: Matthew DeYoung Argot Partners [email protected] 212-600-1902

Media: Argot Partners [email protected]

Source: Bicycle Therapeutics plc

Press Releases

Close

IR Nav Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources →

On August 18, 2026, Charles Swanton resigned as a Class II director of the Board of Directors (the “Board”) of Bicycle Therapeutics plc (the “Company”), as a member of the Board’s committees and as a member of the Company’s Clinical Advisory Board, effective immediately. Dr. Swanton’s resignation was for personal reasons and not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

07/30/26

Download PDF

Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities

Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.

Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Jul. 30, 2026-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates.

“We are pleased with the progress we made during the second quarter. Our financial discipline with refined focus on nuzefatide pevedotin and our next-generation Bicycle conjugate pipeline, including Bicycle® Radioconjugates (BRC®), leaves us well capitalized to pursue our mission to help patients to not only live longer, but also live well,” said Bicycle CEO Kevin Lee, Ph.D. “The encouraging data we presented during the quarter continue to deepen our belief in the potential of our technology to deliver oncology therapeutics with a superior benefit/risk profile against high-value targets like EphA2 and Nectin-4, the former being historically considered undruggable using antibody-based approaches. We believe this profile provides a strong rationale for developing nuzefatide in recurrent pancreatic cancer, where we successfully dosed our first patient in the ongoing Phase 2 trial in April. We remain on track to begin the Phase 1 trial for BT1702, our MT1-MMP targeting BRC, in 2027, backed by compelling human imaging data validating the targeting precision and translatability of our Bicycle® technology.”

Dr Lee added: “It is an honor to welcome world-renowned oncologist Professor Thomas Powles to our Clinical Advisory Board. His deep clinical insights and distinguished leadership in urothelial cancers will be instrumental as we accelerate our efforts to deliver precision-targeted therapies for patients.”

Second Quarter 2026 and Recent Events

  • Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 highlights significant opportunities for nuzefatide pevedotin (nuzefatide), a potentially first-in-class EphA2 targeting Bicycle® Drug Conjugate (BDC®), in EphA2 expressing cancers.

  • As of the February 9, 2026 data cutoff, results from the Phase 1/2 trial evaluating nuzefatide 6.5mg/m2 once every two weeks (Q2W) plus nivolumab 480mg once every four weeks (Q4W) in 14 patients with metastatic urothelial cancer (mUC) who had previously progressed on a checkpoint inhibitor (10 while on enfortumab vedotin) showed a differentiated safety profile as well as promising anti-tumor activity.

  • Preclinical assessment of nuzefatide anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC). Expression of EphA2 was found in all 16 PDAC PDX models. Of the 14 PDAC PDX models assessed for anti-tumor activity, 10 models were sensitive to nuzefatide, six of which showed high sensitivity.

  • Nuzefatide demonstrated potent preclinical anti-tumor activity in EphA2-expressing cell-line-derived xenograft models of head and neck squamous cell carcinoma.

Altogether, Bicycle Therapeutics believes that these data underscore the therapeutic potential for nuzefatide in EphA2-expressing cancers, including pancreatic cancer.

Bicycle Therapeutics is actively enrolling patients in a Phase 2 clinical trial to evaluate efficacy, safety, and pharmacokinetics of nuzefatide in adult patients with recurrent PDAC. The first patient was successfully dosed in April 2026 at the 8mg/m2 Q2W preferred dose for the trial.

  • **Additional human imaging data of a Bicycle® Imaging Agent (BIA) targeting EphA2 in patients with PDAC presented at AACR Annual Meeting 2026.**The German Cancer Consortium (DKTK), part of a cooperative network with the German Cancer Research Center (DKFZ), presented human imaging data conducted with a Bicycle® molecule targeting EphA2 labelled with gallium-68 (EphA2 BIA) in seven patients with histologically confirmed PDAC. Bicycle Therapeutics believes these data validate the potential of EphA2 as a novel target in the treatment of cancer, demonstrate the translatability of preclinical data and highlight the potential of Bicycle® molecules for targeted radioligand therapies and radiopharmaceutical imaging.

Bicycle Therapeutics continues to advance its emerging radioligand pipeline, with the initiation of the first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP targeting BRC, expected in 2027.

  • **Initial Duravelo-2 data presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrates encouraging response rates comparable to published data for standard of care (SOC) and a potentially differentiated safety profile in previously untreated patients with mUC.**Zelenectide pevedotin (zelenectide) is a BDC targeting Nectin-4, a well-validated tumor antigen. The dose optimization stage of the randomized Phase 2 Duravelo-2 trial evaluated two doses of zelenectide – 5mg/m2 weekly (5mg dose) and 6mg/m2 (6mg dose) two weeks on, one week off – in combination with 200mg of pembrolizumab once every three weeks in previously untreated patients with mUC (Cohort 1). Bicycle Therapeutics reached regulatory alignment on the zelenectide 6mg dose as optimal both in combination with pembrolizumab and as a monotherapy. Cohort 1 data were extracted for the interim analysis at Week 27, on July 23, 2025. At the time of the data cut, the median progression-free survival (PFS) was not mature, and the results at the optimal dose showed:

  • 65% (17/26) overall response rate (ORR) regardless of confirmation and blinded independent central review (BICR) confirmed ORR of 58% (15/26) at the 27-week cutoff. Subsequent to the 27-week cutoff, an additional confirmed BICR response was observed, which would result in an ORR of 62% (16/26).

  • Low rates of zelenectide-related adverse events (AEs) of clinical interest were observed, including peripheral neuropathy, sensory (33%); skin reactions (17%); eye disorders (10%).

  • There were no reported instances of zelenectide-related hyperglycemia and no zelenectide-related severe skin reactions of any grade.

  • **Updated Duravelo-1 data presented at 2026 ASCO Annual Meeting demonstrates encouraging median PFS comparable to published data for SOC in previously untreated, cisplatin-ineligible mUC patients.**Updated Phase 1 Duravelo-1 results as of the August 1, 2025 data cutoff evaluating zelenectide at the 5mg dose in combination with pembrolizumab in previously untreated cisplatin-ineligible patients, 45% of whom were classified as Eastern Cooperative Oncology Group (ECOG) performance status of 2, showed:

  • 59% (13/22) ORR regardless of confirmation, 50% confirmed ORR (11/22), and a disease control rate (DCR) of 82%. Of the confirmed responses, 5 (23%) were complete responses and 6 (27%) were partial responses.

  • Median PFS was 13.0 months and median duration of response (mDOR) was not mature at the time of the data cutoff.

Across all patients, the safety and tolerability profile was consistent with other zelenectide data to date. No new safety signals were observed and there were no Grade 4 or Grade 5 zelenectide-related AEs of clinical interest reported.

  • **Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.**Dr. Powles is a Professor of Genitourinary Oncology and Director of Barts Cancer Centre at St Bartholomew’s Hospital, and Lead for Solid Tumor Research at Barts Cancer Institute, London. Dr. Powles is an international leader in the treatment of urothelial cancers, with a research focus spanning from Phase 1 to randomized Phase 3 clinical trials, particularly in translational Phase 2 studies investigating novel targeted and immune therapies. He has played a critical role in leading over twenty randomized clinical trials, resulting in multiple U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals.

Second Quarter 2026 Financial Results

  • Cash and cash equivalents were $510.1 million as of June 30, 2026, compared to $628.1 million as of December 31, 2025. The decrease in cash and cash equivalents is primarily due to cash used in operations, including cash payments for clinical program activities.

  • Research and development (R&D) expenses were $41.2 million for the three months ended June 30, 2026, compared to $71.0 million for the three months ended June 30, 2025. The decrease in expense of $29.8 million was primarily due to decreased clinical program expenses for zelenectide, decreased personnel-related costs and share-based compensation due to our recent workforce reduction announced in March 2026, as well as decreased discovery, platform and other expenses, offset by lower U.K. R&D tax credits period over period.

  • General and administrative (G&A) expenses were $14.0 million for the three months ended June 30, 2026, compared to $18.5 million for the three months ended June 30, 2025. The decrease in expense of $4.5 million was primarily due to decreased professional and consulting fees and decreased personnel-related costs and share-based compensation due to our recent workforce reduction announced in March 2026.

  • Net loss was $50.3 million, or $(0.72) basic and diluted net loss per share, for the three months ended June 30, 2026, compared to net loss of $79.0 million, or $(1.14) basic and diluted net loss per share, for the three months ended June 30, 2025.

About Bicycle TherapeuticsBicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com.

Forward Looking StatementsThis press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”, “promising”, “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of nuzefatide pevedotin, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and the potential development of nuzefatide pevedotin in a number of cancers, including pancreatic cancer; the progress of Bicycle Therapeutics’ clinical trials, reporting data from Bicycle Therapeutics’ clinical trials, including for nuzefatide pevedotin, the timing of EphA2 human imaging data and updates on future clinical development plans for nuzefatide pevedotin; the potential of EphA2 as a novel cancer target and the positive properties of Bicycle® radioligand molecules for radiopharmaceutical use; the development of the Bicycle® radioligands pipeline, including BRCs and BIAs; communications with and feedback from the FDA and other regulatory agencies; Bicycle Therapeutics’ expected financial runway; and the use of Bicycle Therapeutics’ technology through various partnerships to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: the workforce reduction may take longer or result in more significant charges or cash expenditures than anticipated or otherwise negatively impact Bicycle Therapeutics’ and its business plans during and after the period during which the workforce reduction is being executed; uncertainties related to the benefits of the strategic reprioritization; uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics may not realize the intended benefits of its technology or partnerships; the risk that Bicycle Therapeutics may not achieve any of its clinical development strategies; timing of results from clinical trials; whether the outcomes of preclinical studies and prior clinical trials will be predictive of future clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics’ projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle Therapeutics’ actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle Therapeutics’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 17, 2026, as well as in other filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

| Bicycle Therapeutics plc Condensed Consolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) |

| | | | | |

| | | Three Months Ended | | Six Months Ended |

| | | June 30, | | June 30, |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Collaboration revenue | | $ | 629 | | | $ | 2,920 | | | $ | 1,516 | | | $ | 12,897 | |

| Operating expenses: | | | | | | | | | | | | |

| Research and development | | | 41,160 | | | | 71,029 | | | | 90,061 | | | | 130,087 | |

| General and administrative | | | 14,028 | | | | 18,493 | | | | 31,496 | | | | 39,616 | |

| Total operating expenses | | | 55,188 | | | | 89,522 | | | | 121,557 | | | | 169,703 | |

| Loss from operations | | | (54,559 | ) | | | (86,602 | ) | | | (120,041 | ) | | | (156,806 | ) |

| Other income (expense): | | | | | | | | | | | | |

| Interest and other income | | | 4,360 | | | | 7,473 | | | | 9,237 | | | | 15,887 | |

| Interest expense | | | (44 | ) | | | (54 | ) | | | (92 | ) | | | (105 | ) |

| Total other income, net | | | 4,316 | | | | 7,419 | | | | 9,145 | | | | 15,782 | |

| Net loss before income tax provision | | | (50,243 | ) | | | (79,183 | ) | | | (110,896 | ) | | | (141,024 | ) |

| Provision for (benefit from) income taxes | | | 90 | | | | (231 | ) | | | 262 | | | | (1,318 | ) |

| Net loss | | $ | (50,333 | ) | | $ | (78,952 | ) | | $ | (111,158 | ) | | $ | (139,706 | ) |

| Net loss per share, basic and diluted | | $ | (0.72 | ) | | $ | (1.14 | ) | | $ | (1.59 | ) | | $ | (2.02 | ) |

| Weighted average ordinary shares outstanding, basic and diluted | | | 69,804,828 | | | | 69,252,009 | | | | 69,744,485 | | | | 69,224,629 | |

| Balance Sheets Data (In thousands) (Unaudited) |

| | | | | | | |

| | | | June 30, | | | December 31, |

| | | | 2026 | | | 2025 |

| Cash and cash equivalents | | $ | 510,052 | | $ | 628,110 |

| Working capital | | | 527,601 | | | 625,901 |

| Total assets | | | 606,578 | | | 717,597 |

| Total shareholders’ equity | | | 510,255 | | | 609,977 |

View source version on businesswire.com: https://www.businesswire.com/news/home/20260730302807/en/

Investors: Matthew DeYoung Argot Partners [email protected] 212-600-1902

Media: Argot Partners [email protected]

Source: Bicycle Therapeutics plc

Press Releases

Close

IR Nav Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources →

Prompts

Bicycle Therapeutics plc (ticker BCYC), listed in United States.

ETFs Holding Bicycle Therapeutics plc

ETF Weight in ETF Shares Market value As of
MEDX 0.28% 12,584 $ 53.356K Jun 30, 2026
APIE 0.00% 11,719 $ 48.399K Aug 31, 2026